Presented
by

Presented by Oxford Global

Discover PLUS Pass

All Biologics Content

Bringing you the latest research in Proteins and Antibodies, Peptides, and Oligonucleotides through a range of Speaker Interviews, Industry Insights, and Expert Opinions.
Industry Spotlight
WuXi Biologics and GSK Enter License Agreement for Bispecific Development
The Pharma giants have partnered to advance the development of bispecific T cell engaging antibodies using WuXi’s platforms.
Edited by Cara Digby-Patel |
14 July 2023
Bispecifics
Insight Article
T Cell Engagement and Activation: New Developments
As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape.
Edited by Cara Digby-Patel |
10 July 2023
Bispecifics
Insight Article
The Bispecific Antibody Landscape
Key opinion leaders explore recent developments for bispecific antibodies, from new delivery technologies to the complexity of their pharmacokinetic profiles.
Edited by Cara Digby-Patel |
12 April 2023
Bispecifics
Industry Spotlight
Regeneron’s New Bispecific: A Toxic Success?
Regeneron announced that their bispecific odronextamab had the highest recorded complete response rate for follicular lymphoma, but the therapeutic antibody’s safety profile has thrown up several concerns.
Edited by Cara Digby-Patel |
14 December 2022
Bispecifics
Discussion Group Report
Exploring & Developing Various Biotherapeutic Modalities
Galahad Deperalta, Senior Scientist and Innovation Group Leader at Genentech, leads a Discussion Group on the next generation of biotherapeutic development.
Edited by Tia Byer |
27 October 2022
Bispecifics
Industry Spotlight
Gilead Pay Big Bucks for MacroGenics' Blood-Cancer Targeting Bispecific
Gilead announced a $1.7 billion licence-option deal for MacroGenics’ MGD024 bispecific once Phase I trials conclude.
Edited by Cara Digby-Patel |
19 October 2022
Bispecifics
Discussion Group Report
Bispecific Antibodies for Solid Tumours
Laura von Schantz, Vice President of Discovery at Alligator Bioscience, leads a discussion on the current and future opportunities of bispecific antibodies for solid tumour treatment.
Edited by Tia Byer |
31 July 2022
Bispecifics
Industry Spotlight
AstraZeneca Buys T Cell Engager for $100 Million
Pharma giant makes a major investment in improving the standards of care in B cell malignancies.
Edited by Tia Byer |
08 July 2022
Bispecifics
Industry Spotlight
Why Drug Delivery is Key to New Drug Discovery
Method of delivery is just as important as discovering new medicines.
Edited by Tia Byer |
01 July 2022
Bispecifics
Insight Article
Broadening Horizons for Bispecific Effector Cell Redirection
Key opinion leaders share their thoughts on the prospect of effector cell redirection and cell engagers at Biologics UK: In-Person 2022.
Edited by Tia Byer |
07 June 2022
Bispecifics

Search by Keyword

Filter by Subject Area

Biologics Series – Subjects

Filter by Content Type

Resource Formats (incl. Industry Spotlight)

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Twitter Linkedin-in

Event Series

About

Careers

Legal

Copyright Oxford Global Marketing Limited. All rights reserved.